



thor medical

TRMED – Executive Management Share Purchase

12.6.2026 16:20:54 CEST | Thor Medical ASA | Mandatory notification of trade primary insiders

Oslo, Norway, 12 June 2026 – Thor Medical ASA announces that Mathias Nilsen Reierth, Head of Communications & Corporate Affairs and a primary insider of the company, has purchased 27,777 shares in the company at an average price of NOK 4.14 per share.

Notification of the transaction in accordance with the Market Abuse Regulation Article 19 is attached to this announcement.

For further information please contact:

Brede Ellingsæter

Chief Financial Officer

Tel: +47 472 38 440

Email: brede.ellingseter@thormedical.no

Mathias Nilsen Reierth

Head of Communications and Corporate Affairs

Tel: +47 988 05 724

Email: mathias.reierth@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com. - <http://www.thormedical.com>

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Securities Trading Act.

Attachments

- [Download announcement as PDF.pdf](#)
- [20260612 - TRMED - PDMR notification MAR PDF.pdf](#)